Literature DB >> 36042957

Pediatric AIDS-Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling.

Edmund V Capparelli1.   

Abstract

Entities:  

Keywords:  HIV; antiretrovirals; pediatrics; pharmacodynamics; pharmacokinetics; population pharmacokinetics

Year:  2022        PMID： 36042957      PMCID： PMC9400182          DOI： 10.5863/1551-6776-27.6.482

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


× No keyword cloud information.
  25 in total

1.  Reference values for serum creatinine in children younger than 1 year of age.

Authors:  Dirk P Boer; Yolanda B de Rijke; Wim C Hop; Karlien Cransberg; Eiske M Dorresteijn
Journal:  Pediatr Nephrol       Date:  2010-05-27       Impact factor: 3.714

2.  Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.

Authors:  M Mirochnick; E Capparelli; W Dankner; R S Sperling; R van Dyke; S A Spector
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: pediatric AIDS Clinical Trials Group Protocol 076--results and treatment recommendations.

Authors:  E M Connor; L M Mofenson
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129

4.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

5.  Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

Authors:  Edmund V Capparelli; Janet A Englund; James D Connor; Stephen A Spector; Ross E McKinney; Paul Palumbo; Carol J Baker
Journal:  J Clin Pharmacol       Date:  2003-02       Impact factor: 3.126

6.  Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

Authors:  Ellen G Chadwick; Edmund V Capparelli; Ram Yogev; Jorge A Pinto; Brian Robbins; John H Rodman; Jie Chen; Paul Palumbo; Leslie Serchuck; Elizabeth Smith; Michael Hughes
Journal:  AIDS       Date:  2008-01-11       Impact factor: 4.177

7.  Pharmacokinetics and tolerance of zidovudine in preterm infants.

Authors:  Edmund V Capparelli; Mark Mirochnick; Wayne M Dankner; Suzette Blanchard; Lynne Mofenson; George D McSherry; Hannah Gay; Gregory Ciupak; Betsy Smith; James D Connor
Journal:  J Pediatr       Date:  2003-01       Impact factor: 4.406

8.  Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.

Authors:  Elizabeth J McFarland; Coleen K Cunningham; Petronella Muresan; Edmund V Capparelli; Charlotte Perlowski; Patricia Morgan; Betsy Smith; Rohan Hazra; Lynette Purdue; Paul A Harding; Gerhard Theron; Hilda Mujuru; Allison Agwu; Murli Purswani; Mobeen H Rathore; Britta Flach; Alison Taylor; Bob C Lin; Adrian B McDermott; John R Mascola; Barney S Graham
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 7.759

9.  Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.

Authors:  Adrie Bekker; Helena Rabie; Nicolas Salvadori; Samantha du Toit; Kanchana Than-In-At; Marisa Groenewald; Isabelle Andrieux-Meyer; Mukesh Kumar; Ratchada Cressey; James Nielsen; Edmund Capparelli; Marc Lallemant; Mark F Cotton; Tim R Cressey
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-01       Impact factor: 3.771

10.  Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.

Authors:  Jerry Li; Mina Nikanjam; Coleen K Cunningham; Elizabeth J McFarland; Emily E Coates; Katherine V Houser; Bob C Lin; Adrian B McDermott; Britta Flach; Lucio Gama; Richard A Koup; Barney S Graham; John R Mascola; Julie E Ledgerwood; Edmund V Capparelli
Journal:  Clin Pharmacol Ther       Date:  2020-10-03       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.